In comparison, Felker et al. investigated the effect of NT-proBNP on the 6MWD in a post-hoc analysis of HF-ACTION, a randomized controlled clinical trial including 2331 patients with heart failure and LVEF below 35%. The gene discussed is NPPB; the disease is heart failure.